vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and LCNB CORP (LCNB). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $15.0M, roughly 1.6× CHAMPIONS ONCOLOGY, INC.). LCNB CORP runs the higher net margin — 23.7% vs 1.8%, a 21.9% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs 5.1%). LCNB CORP produced more free cash flow last quarter ($33.4M vs $-2.0M). Over the past eight quarters, LCNB CORP's revenue compounded faster (15.7% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
CSBR vs LCNB — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $23.9M |
| Net Profit | $268.0K | $5.7M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 29.2% |
| Net Margin | 1.8% | 23.7% |
| Revenue YoY | 11.5% | 5.1% |
| Net Profit YoY | -63.2% | -7.6% |
| EPS (diluted) | $0.02 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $23.9M | ||
| Q3 25 | $14.0M | $23.8M | ||
| Q2 25 | $12.4M | $22.8M | ||
| Q1 25 | $17.0M | $21.5M | ||
| Q4 24 | $13.5M | $22.7M | ||
| Q3 24 | $14.1M | $21.4M | ||
| Q2 24 | $14.0M | $19.3M | ||
| Q1 24 | $12.0M | $17.8M |
| Q4 25 | $268.0K | $5.7M | ||
| Q3 25 | $-436.0K | $6.9M | ||
| Q2 25 | $-1.8M | $5.9M | ||
| Q1 25 | $4.5M | $4.6M | ||
| Q4 24 | $728.0K | $6.1M | ||
| Q3 24 | $1.3M | $4.5M | ||
| Q2 24 | $-109.0K | $925.0K | ||
| Q1 24 | $-2.5M | $1.9M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 29.2% | ||
| Q3 25 | -3.8% | 35.6% | ||
| Q2 25 | -16.2% | 31.6% | ||
| Q1 25 | 26.4% | 25.6% | ||
| Q4 24 | 5.4% | 32.9% | ||
| Q3 24 | 9.5% | 24.9% | ||
| Q2 24 | -1.9% | 4.9% | ||
| Q1 24 | -21.4% | 12.5% |
| Q4 25 | 1.8% | 23.7% | ||
| Q3 25 | -3.1% | 29.1% | ||
| Q2 25 | -14.9% | 26.0% | ||
| Q1 25 | 26.4% | 21.4% | ||
| Q4 24 | 5.4% | 27.0% | ||
| Q3 24 | 9.3% | 21.2% | ||
| Q2 24 | -0.8% | 4.8% | ||
| Q1 24 | -21.1% | 10.7% |
| Q4 25 | $0.02 | $0.40 | ||
| Q3 25 | $-0.03 | $0.49 | ||
| Q2 25 | $-0.12 | $0.41 | ||
| Q1 25 | $0.31 | $0.33 | ||
| Q4 24 | $0.05 | $0.44 | ||
| Q3 24 | $0.09 | $0.31 | ||
| Q2 24 | $-0.01 | $0.07 | ||
| Q1 24 | $-0.19 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $21.6M |
| Total DebtLower is stronger | — | $104.4M |
| Stockholders' EquityBook value | $4.2M | $273.9M |
| Total Assets | $30.2M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $21.6M | ||
| Q3 25 | $10.3M | $35.9M | ||
| Q2 25 | $9.8M | $49.8M | ||
| Q1 25 | $3.2M | $37.7M | ||
| Q4 24 | $2.8M | $35.7M | ||
| Q3 24 | $2.9M | $39.4M | ||
| Q2 24 | $2.6M | $34.9M | ||
| Q1 24 | $4.5M | $33.0M |
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $155.7M | ||
| Q2 24 | — | $162.2M | ||
| Q1 24 | — | $162.6M |
| Q4 25 | $4.2M | $273.9M | ||
| Q3 25 | $3.5M | $269.9M | ||
| Q2 25 | $3.8M | $263.5M | ||
| Q1 25 | $5.5M | $258.7M | ||
| Q4 24 | $681.0K | $253.0M | ||
| Q3 24 | $-332.0K | $253.2M | ||
| Q2 24 | $-1.9M | $245.2M | ||
| Q1 24 | $-2.1M | $233.7M |
| Q4 25 | $30.2M | $2.2B | ||
| Q3 25 | $30.5M | $2.2B | ||
| Q2 25 | $32.3M | $2.3B | ||
| Q1 25 | $30.6M | $2.3B | ||
| Q4 24 | $25.2M | $2.3B | ||
| Q3 24 | $24.9M | $2.3B | ||
| Q2 24 | $26.1M | $2.4B | ||
| Q1 24 | $26.8M | $2.3B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $34.4M |
| Free Cash FlowOCF − Capex | $-2.0M | $33.4M |
| FCF MarginFCF / Revenue | -13.1% | 140.2% |
| Capex IntensityCapex / Revenue | 1.6% | 4.0% |
| Cash ConversionOCF / Net Profit | -6.47× | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $34.4M | ||
| Q3 25 | $600.0K | $14.0M | ||
| Q2 25 | $6.9M | $5.5M | ||
| Q1 25 | $490.0K | $2.2M | ||
| Q4 24 | $-283.0K | $93.2M | ||
| Q3 24 | $311.0K | $11.9M | ||
| Q2 24 | $-1.8M | $54.9M | ||
| Q1 24 | $-919.0K | $-11.9M |
| Q4 25 | $-2.0M | $33.4M | ||
| Q3 25 | $554.0K | $13.7M | ||
| Q2 25 | $6.6M | $5.2M | ||
| Q1 25 | $448.0K | $2.1M | ||
| Q4 24 | $-377.0K | $89.4M | ||
| Q3 24 | — | $10.5M | ||
| Q2 24 | $-1.8M | $53.8M | ||
| Q1 24 | $-1.0M | $-12.8M |
| Q4 25 | -13.1% | 140.2% | ||
| Q3 25 | 4.0% | 57.4% | ||
| Q2 25 | 53.5% | 23.0% | ||
| Q1 25 | 2.6% | 10.0% | ||
| Q4 24 | -2.8% | 394.0% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | -13.0% | 278.6% | ||
| Q1 24 | -8.4% | -71.8% |
| Q4 25 | 1.6% | 4.0% | ||
| Q3 25 | 0.3% | 1.3% | ||
| Q2 25 | 2.0% | 1.0% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.7% | 16.7% | ||
| Q3 24 | 0.0% | 6.7% | ||
| Q2 24 | 0.0% | 5.9% | ||
| Q1 24 | 0.8% | 4.8% |
| Q4 25 | -6.47× | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | 0.11× | 0.48× | ||
| Q4 24 | -0.39× | 15.23× | ||
| Q3 24 | 0.24× | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | — | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
LCNB
Segment breakdown not available.
